These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28817621)

  • 1. Re-evaluation of the cost-effectiveness and effects of childhood rotavirus vaccination in Norway.
    Hansen Edwards C; de Blasio BF; Salamanca BV; Flem E
    PLoS One; 2017; 12(8):e0183306. PubMed ID: 28817621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of childhood rotavirus vaccination in Germany.
    Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
    Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
    Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
    Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of childhood rotavirus vaccination in Taiwan.
    Wu CL; Yang YC; Huang LM; Chen KT
    Vaccine; 2009 Mar; 27(10):1492-9. PubMed ID: 19186200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand.
    Luangasanatip N; Mahikul W; Poovorawan K; Cooper BS; Lubell Y; White LJ; Teerawattananon Y; Pan-Ngum W
    Vaccine; 2021 Mar; 39(9):1402-1414. PubMed ID: 33531197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of the introduction of rotavirus vaccine in Hong Kong.
    Yeung KHT; Lin SL; Clark A; McGhee SM; Janusz CB; Atherly D; Chan KC; Nelson EAS
    Vaccine; 2021 Jan; 39(1):45-58. PubMed ID: 33221066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.
    Standaert B; Parez N; Tehard B; Colin X; Detournay B
    Appl Health Econ Health Policy; 2008; 6(4):199-216. PubMed ID: 19382820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: comparison between Rotarix and RotaTeq vaccines.
    van Hoek AJ; Ngama M; Ismail A; Chuma J; Cheburet S; Mutonga D; Kamau T; Nokes DJ
    PLoS One; 2012; 7(10):e47511. PubMed ID: 23115650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines.
    Pecenka C; Debellut F; Bar-Zeev N; Anwari P; Nonvignon J; Shamsuzzaman M; Clark A
    Vaccine; 2018 Nov; 36(49):7472-7478. PubMed ID: 30420039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium.
    Bilcke J; Van Damme P; Beutels P
    Med Decis Making; 2009; 29(1):33-50. PubMed ID: 18948433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of rotavirus vaccination in Australia.
    Newall AT; Beutels P; Macartney K; Wood J; MacIntyre CR
    Vaccine; 2007 Dec; 25(52):8851-60. PubMed ID: 18022735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of a rotavirus immunization program for the United States.
    Tucker AW; Haddix AC; Bresee JS; Holman RC; Parashar UD; Glass RI
    JAMA; 1998 May; 279(17):1371-6. PubMed ID: 9582045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia.
    Loganathan T; Ng CW; Lee WS; Hutubessy RCW; Verguet S; Jit M
    Health Policy Plan; 2018 Mar; 33(2):204-214. PubMed ID: 29228339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting.
    Bruijning-Verhagen P; van Dongen JAP; Verberk JDM; Pijnacker R; van Gaalen RD; Klinkenberg D; de Melker HE; Mangen MJ
    BMC Med; 2018 Sep; 16(1):168. PubMed ID: 30196794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An economic analysis of rotavirus vaccination in Italy.
    Giammanco MD; Coniglio MA; Pignato S; Giammanco G
    Vaccine; 2009 Jun; 27(29):3904-11. PubMed ID: 19446934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost and cost-effectiveness of childhood vaccination against rotavirus in France.
    Melliez H; Levybruhl D; Boelle PY; Dervaux B; Baron S; Yazdanpanah Y
    Vaccine; 2008 Jan; 26(5):706-15. PubMed ID: 18166250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Rotavirus Vaccination in France-Accounting for Indirect Protection.
    Yamin D; Atkins KE; Remy V; Galvani AP
    Value Health; 2016; 19(6):811-819. PubMed ID: 27712709
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.